Patient groups are mounting a pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments. Click here to view original post… […]
The Sackler family members who own Purdue Pharma agreed to pay up to $6 billion to settle a bankruptcy plan and issued a statement regretting their role in the opioid… Click here to view original post… […]
The South African government does not plan to buy the Merck Covid-19 antiviral pill, called molnupiravir, due to the cost. Click here to view original post… […]
An FDA advisory panel decided Eli Lilly and its Chinese partner, Innovent Biologics, should conduct more studies of a lung cancer drug to win approval. Click here to view original post… […]
Biosplice, once the world’s most valuable biotech startup, is laying off nearly a quarter of its workforce and has stopped internal development of a hair-loss treatment. Click here to view original post… […]
Biogen is selling its stake in a biosimilars joint venture for $2.3 billion, adding to the company’s cash reserves as investors clamor for M&A. Click here to view original post… […]
Alzheimer’s patient groups are planning publicity and lobbying campaigns to protest a Medicare coverage proposal they say could delay the use of new drugs for 10 years. Click here to view original post… […]
Desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment, Biogen has a shopping list of potential acquisitions. Click here to view original post… […]
Medicare may have released a plan to restrict access to the controversial Biogen Alzheimer’s drug, but the biggest losers may be other drug makers readying treatments. Click here to view original post… […]
Medicare plans to cover the controversial Biogen Alzheimer’s drug, but only for certain patients enrolled in clinical trials. Click here to view original post… […]
Copyright © 2022 Biotech Networks, LLC
